Research Roundup: Advancing Cancer Research with Polyclonal Antibodies

Author:  R&D Team, Atlas Antibodies AB, Sweden

At the forefront of cancer research, primary antibodies have become indispensable tools for researchers, enabling the dissection of the molecular mechanisms of various human cancer. Atlas Antibodies is proud to be a part of this global mission, providing enhanced validated primary antibodies utilized in cutting-edge cancer research worldwide.

At Atlas Antibodies, we are deeply committed to supporting cancer research. By providing reliable and specific antibodies, we are enabling researchers around the world to push the boundaries of cancer biology and biomarker discoveries. Our mission is to continue contributing to the global fight against cancer, empowering scientists to achieve breakthroughs that will ultimately improve patient outcomes.

Targeted Detection in Human Cancer: Protein Localization and Quantification

Polyclonal antibodies offer several advantages in research, including their ability to recognize multiple epitopes on a target antigen, which enhances sensitivity and provides a broader detection range. This makes them particularly valuable in detecting low-abundance proteins and in applications where antigen heterogeneity is a concern.

By using immunohistochemistry  and immunofluorescence applications, primary antibodies help determine the spatial distribution of proteins within cells and tissues. This is vital for understanding how proteins' locations change in cancerous versus normal cells, providing insights into tumor biology.

Through techniques like Western blotting, enzyme-linked immunosorbent assays (ELISA), and mass spectrometry, primary antibodies enable the quantification of protein levels. This quantification is crucial for assessing protein expression changes in cancer, identifying potential biomarkers, and evaluating the effects of therapeutic interventions. 

Understanding the Molecular Mechanisms of Cancer

Our Triple A Polyclonal antibodies have been integral in studies investigating various cancers, such as hepatocellular carcinoma, glioblastoma, ovarian and breast cancer and more. Our antibodies are not only trusted by researchers but are also making significant contributions to the discovery of novel cancer biomarkers, the understanding of tumor biology, and the development of innovative therapeutic strategies.

For instance, the potential of GSPT1 as a therapeutic target in glioblastoma, identified through research involving our anti-GSPT1 antibody, is a prime example of how our products are aiding in the development of targeted cancer therapies.

In hepatocellular carcinoma, the upregulation of exon 10-inclusive SREK1 through SRSF10, identified using our anti-SRSF10 antibodies, has been shown to act as an oncogenic driver, a finding published in Nature Communications.

Similarly, in the same cancer type, the mTORC1-mediated degradation of ARID1A, explored with our anti-ARID1A antibodies, has provided insights into oncogenic chromatin remodeling.

In ovarian cancer research, our antibodies against LAMC1 and STX5 have facilitated the identification of proteomic profiles that correlate with patient outcomes, offering new avenues for personalized medicine.

These and other studies underscore the critical role that our TripleA polyclonals antibodies play in uncovering the molecular underpinnings of cancer mechansims and progression. 

Mapping the human proteome one antibody at the time.

Join the “HPA”movement!

Here is a list of recent publications featuring our Triple A Polyclonals™ antibodies. These are the very same polyclonal antibodies that have been used to build the Human Protein Atlas, a comprehensive resource for exploring protein expression across different tissues and diseases.…and this is why our polyclonals are designated with the prefix "HPA," which stands for Human Protein Atlas. Did you know it?

Breast cancer:

Coillard L, et al. The NFAT3/RERG Complex in Luminal Breast Cancers Is Required to Inhibit Cell Invasion and May Be Correlated With an Absence of Axillary Lymph Nodes Colonization. Front Oncol. 2022. 12:1016189. PMID: 35847954
Featured antibody: anti-NFATC4/NAFT3 (Cat. HPA031641)

Blawski R, et al. Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer. Cell Rep. 2024 May 28;43(5):114174. Epub 2024. PMID: 38700982
Featured antibody: anti-KMT2D (Cat. HPA035877)

Couto JP, et al. Nicotinamide N-methyltransferase sustains a core epigenetic program that promotes metastatic colonization in breast cancer. EMBO J. 2023 Jul 3;42(13):e112559. Epub 2023. PMID: 37259596
Featured antibody: anti-PRDM5 (Cat. HPA051406)

An J, et al. EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis. Oncogene. 2019 Mar;38(12):2123-2134. Epub 2018. PMID: 30455428
Featured antibody: anti-EGFL6 (Cat. HPA001838)

Lien HC, et al. Transcriptomic alterations underlying metaplasia into specific metaplastic components in metaplastic breast carcinoma. Breast Cancer Res. 2023 Jan 27;25(1):11. PMID: 36707876
Featured antibodies: anti-PDGFRA (Cat. HPA004947), anti-COL9A3 (Cat. HPA040125), anti-PYCARD (Cat. HPA054496)

Reina J, et al. LHPP expression in triple-negative breast cancer promotes tumor growth and metastasis by modulating the tumor microenvironment. bioRxiv [Preprint]. 2024 Apr 23:2024.04.19.590151. PMID: 38712081
Featured antibody: anti-LHPP (Cat. HPA009163)

Cheng Z, et al. Disruption of ZNF334 promotes triple-negative breast carcinoma malignancy through the SFRP1/ Wnt/β-catenin signaling axis. Cell Mol Life Sci. 2022 May 4;79(5):280. PMID: 35507080
Featured antibody: anti-ZNF334 (Cat. HPA050022)

Colorectal cancer:

Kurilla A, et al. Studying the Association of TKS4 and CD2AP Scaffold Proteins and Their Implications in the Partial Epithelial-Mesenchymal Transition (EMT) Process. Int J Mol Sci. 2023 Oct 13;24(20):15136. PMID: 37894817
Featured antibody: anti-SH3PXD2B (Cat. HPA036471)

 
Zhang B, et al. The chromatin remodeler CHD6 promotes colorectal cancer development by regulating TMEM65-mediated mitochondrial dynamics via EGF and Wnt signaling. Cell Discov. 2022 Dec 6;8(1):130. PMID: 36473865
Featured antibody: anti-TMEM65 (Cat. HPA025020)

 
Aluksanasuwan S, et al. Proteomic insights into the regulatory function of ARID1A in colon cancer cells. Oncol Lett. 2024 Jun 21;28(2):392. PMID: 38966585
Featured antibody: anti-ARID1A (Cat. HPA005456)

Gastric & Esophageal cancer:

Murtough S, et al. Investigating iRHOM2-Associated Transcriptional Changes in Tylosis With Esophageal Cancer. Gastro Hep Adv. 2023 Dec 26;3(3):385-395. PMID: 39131151
Featured antibody: anti-GRHL2 (Cat. HPA004820)

 Kim B, et al. Predictive biomarkers for metachronous gastric cancer development after endoscopic resection of early gastric cancer. Cancer Med. 2024 Aug;13(16):e70104. PMID: 39171503
Featured antibody: anti-KDF1 (Cat. HPA028639)

Vilarinho T, et al. MISP Is Overexpressed in Intestinal Metaplasia and Gastric Cancer. Curr Oncol. 2024 May 14;31(5):2769-2779. PMID: 38785491
Featured antibody: anti-MISP (Cat. HPA062232)

Glioma & Glioblastoma:
 

Sasayama T, et al. Potential of GSPT1 as a novel target for glioblastoma therapy. Cell Death Dis. 2024 Aug 8;15(8):572. PMID: 39117611
Featured antibody: anti-GSPT1 (Cat. HPA052488)

Li J, et al. PRAMEF12, a novel cancer/testis gene, regulates proliferation and apoptosis to promote progression of glioma. Biomark Med. 2024;18(8):385-397. Epub 2024. PMID: 38913622  
Featured antibody: anti-PRAMEF12 (Cat. HPA045286)

Yuan Y, et al. The E3 ubiquitin ligase HUWE1 acts through the N-Myc-DLL1-NOTCH1 signaling axis to suppress glioblastoma progression. Cancer Commun (Lond). 2022 Sep;42(9):868-886. Epub 2022. PMID: 35848447
Featured antibody: anti-HUWE1 (Cat. HPA002548)

Abdoli Shadbad M, et al. HSV1 microRNAs in glioblastoma development: an in silico study. Sci Rep. 2024 Jan 2;14(1):27. PMID: 38167429
Featured antibody: anti-PDGFC (Cat. HPA009134)

Hepatocellular carcinoma

Chang C, et al. The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma. Nat Commun. 2022 Mar 16;13(1):1363. PMID: 35296659
Featured antibodies: anti-SRSF10 (Cat. HPA053831), anti-SRSF10 (Cat. HPA053805)

 Zhang S, et al. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma. Cancer Res. 2021 Nov 15;81(22):5652-5665. PMID: 34429326
Featured antibody: anti-ARID1A (Cat. HPA005456)

Failli M, et al. Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response. Hepatology. 2024 Jul 1;80(1):55-68. PMID: 37729391
Featured antibody: anti-CDK9 (Cat. HPA006738)

Tian J, et al. Hepatitis B-related hepatocellular carcinoma: classification and prognostic model based on programmed cell death genes. Front Immunol. 2024 May 10;15:1411161. PMID: 38799437
Featured antibody: anti-DLAT (Cat. HPA040786)

Lung cancer:

Machour FE, et al. Harnessing DNA replication stress to target RBM10 deficiency in lung adenocarcinoma. Nat Commun. 2024 Jul 30;15(1):6417. PMID: 39080280
Featured antibody: anti-RBM10 (Cat. HPA034972)

Ma X, et al. Spatial Landscape of Malignant Pleural and Peritoneal Mesothelioma Tumor Immune Microenvironments. Cancer Res Commun. 2024 Aug 1;4(8):2133-2146. PMID: 38994676
Featured antibody: anti-NF2 (Cat. HPA003097)

Ko JH, et al. Small Cell Lung Cancer Plasticity Enables NFIB-Independent Metastasis. Cancer Res. 2024 Jan 16;84(2):226-240. PMID: 37963187
Featured antibody: anti-UCHL1 (Cat. HPA005993)

Park SS, et al. Targeting phosphomevalonate kinase enhances radiosensitivity via ubiquitination of the replication protein A1 in lung cancer cells. Cancer Sci. 2023 Sep;114(9):3583-3594. PMID: 37650703
Featured antibodies: anti-PMVK (Cat. HPA029900), anti-MRE11 (Cat. HPA002691), anti-RPA1 (Cat. HPA006914)

Melanoma:

Schörghofer D, et al. Late stage melanoma is hallmarked by low NLGN4X expression leading to HIF1A accumulation. Br J Cancer. 2024 Aug;131(3):468-480. PMID: 38902533
Featured antibodies: anti-NLGN4X (Cat. HPA001651), anti-VBP1 (Cat. HPA023230)

Pancreatic cancer:

Kisling SG, et al. A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2023 Sep 15;29(18):3759-3770. PMID: 37432996
Featured antibodies: anti-PDIA4 (Cat. HPA006140), anti-EIF4G1 (Cat. HPA028487),  anti-MRPS10 (Cat. HPA029134)

Tinsley SL, et al. KRAS-mediated upregulation of CIP2A promotes suppression of PP2A-B56α to initiate pancreatic cancer development. bioRxiv [Preprint]. 2024 May 23:2023.07.01.547283. PMID: 38826439
Featured antibody: anti-KIAA1524 (Cat. HPA039570)

Prostate cancer:

Ippolito L, et al. Lactate supports cell-autonomous ECM production to sustain metastatic behavior in prostate cancer. EMBO Rep. 2024 Aug;25(8):3506-3531. Epub 2024. PMID: 38907027
Featured antibody: anti-P4HA1 (Cat. HPA007599)

Renal cancer:

Beothe T, et al. Increased level of TXNIP and nuclear translocation of TXN is associated with end stage renal disease and development of multiplex renal tumours. BMC Nephrol. 2024 Jul 17;25(1):227. PMID: 39020292
Featured antibody: anti-TXN (Cat. HPA055752)

 

Ovarian Cancer:

Ji Jx  et al. The proteome of clear cell ovarian carcinoma. J Pathol. 2022 Dec;258(4):325-338. PMID: 36031730
Featured antibody: anti-LAMC1 (Cat. HPA001909)

Quiralte M, et al., Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancer. J Clin Invest. 2024 Apr 2;134(10):e176161. PMID: 38564289
Featured antibody: anti-STX5 (Cat. HPA001358)

 

READ MORE BLOGS!